BACKGROUND: Demethylating agents may alter the expression of genes involved in chemotherapy resistance. We conducted a phase I trial to determine the toxicity and molecular effects of the demethylating agent, decitabine, followed by doxorubicin and cyclophosphamide in children with refractory solid tumors. PROCEDURE: Stratum A included children with any solid tumor; Stratum B included neuroblastoma patients only. Patients received a 1-hr decitabine infusion for 7 days, followed by doxorubicin (45 mg/m(2)) and cyclophosphamide (1 g/m(2)) on day 7. Pharmacokinetic studies were performed after the first dose of decitabine. Biological studies included methylation and gene expression analyses of caspase-8, MAGE-1 and fetal hemoglobin (HbF), and expression profiling of pre- and post-treatment peripheral blood and bone marrow cells. RESULTS: The maximum-tolerated dose of decitabine was 5 mg/m(2)/day for 7 days. Dose-limiting toxicities at 10 mg/m(2)/day were neutropenia and thrombocytopenia. Decitabine exhibited rapid clearance from plasma. Three of 9 patients in Stratum A and 4/12 patients in Stratum B had stable disease for > or = 4 months. Sustained MAGE-1 demethylation and increased HbF expression were observed in the majority of patients post-treatment (12/20 and 14/16, respectively). Caspase-8 promoter demethylation and gene expression were seen in 2/7 bone marrow samples. Differentially expressed genes were identified by microarray analysis. CONCLUSION: Low-dose decitabine when combined with doxorubicin/cyclophosphamide has tolerable toxicity in children. However, doses of decitabine capable of producing clinically relevant biologic effects were not well tolerated with this combination. Alternative strategies of combining demethylating agents with non-cytotoxic, biologically targeted agents such as histone deacetylase inhibitors should be explored. Copyright 2010 Wiley-Liss, Inc.
BACKGROUND: Demethylating agents may alter the expression of genes involved in chemotherapy resistance. We conducted a phase I trial to determine the toxicity and molecular effects of the demethylating agent, decitabine, followed by doxorubicin and cyclophosphamide in children with refractory solid tumors. PROCEDURE: Stratum A included children with any solid tumor; Stratum B included neuroblastomapatients only. Patients received a 1-hr decitabine infusion for 7 days, followed by doxorubicin (45 mg/m(2)) and cyclophosphamide (1 g/m(2)) on day 7. Pharmacokinetic studies were performed after the first dose of decitabine. Biological studies included methylation and gene expression analyses of caspase-8, MAGE-1 and fetal hemoglobin (HbF), and expression profiling of pre- and post-treatment peripheral blood and bone marrow cells. RESULTS: The maximum-tolerated dose of decitabine was 5 mg/m(2)/day for 7 days. Dose-limiting toxicities at 10 mg/m(2)/day were neutropenia and thrombocytopenia. Decitabine exhibited rapid clearance from plasma. Three of 9 patients in Stratum A and 4/12 patients in Stratum B had stable disease for > or = 4 months. Sustained MAGE-1 demethylation and increased HbF expression were observed in the majority of patients post-treatment (12/20 and 14/16, respectively). Caspase-8 promoter demethylation and gene expression were seen in 2/7 bone marrow samples. Differentially expressed genes were identified by microarray analysis. CONCLUSION: Low-dose decitabine when combined with doxorubicin/cyclophosphamide has tolerable toxicity in children. However, doses of decitabine capable of producing clinically relevant biologic effects were not well tolerated with this combination. Alternative strategies of combining demethylating agents with non-cytotoxic, biologically targeted agents such as histone deacetylase inhibitors should be explored. Copyright 2010 Wiley-Liss, Inc.
Authors: David S Schrump; Maria R Fischette; Dao M Nguyen; Ming Zhao; Xinmin Li; Tricia F Kunst; Ana Hancox; Julie A Hong; G Aaron Chen; Vitaliy Pishchik; William D Figg; Anthony J Murgo; Seth M Steinberg Journal: Clin Cancer Res Date: 2006-10-01 Impact factor: 12.531
Authors: Allen S Yang; Ketan D Doshi; Sang-Woon Choi; Joel B Mason; Rajan K Mannari; Vazganush Gharybian; Rene Luna; Asif Rashid; Lanlan Shen; Marcos R H Estecio; Hagop M Kantarjian; Guillermo Garcia-Manero; Jean-Pierre J Issa Journal: Cancer Res Date: 2006-05-15 Impact factor: 12.701
Authors: Kim Appleton; Helen J Mackay; Ian Judson; Jane A Plumb; Carol McCormick; Gordon Strathdee; Chooi Lee; Sophie Barrett; Sarah Reade; Dalal Jadayel; Adrian Tang; Katharine Bellenger; Lynsay Mackay; Albert Setanoians; Andreas Schätzlein; Chris Twelves; Stanley B Kaye; Robert Brown Journal: J Clin Oncol Date: 2007-10-10 Impact factor: 44.544
Authors: Amanda F Cashen; Ajit K Shah; Laura Todt; Nicholas Fisher; John DiPersio Journal: Cancer Chemother Pharmacol Date: 2007-06-13 Impact factor: 3.333
Authors: Maryse Lemaire; Guy G Chabot; Noël Jm Raynal; Louise F Momparler; Annie Hurtubise; Mark L Bernstein; Richard L Momparler Journal: BMC Cancer Date: 2008-05-02 Impact factor: 4.430
Authors: Marie Morfouace; Anang Shelat; Megan Jacus; Burgess B Freeman; David Turner; Sarah Robinson; Frederique Zindy; Yong-Dong Wang; David Finkelstein; Olivier Ayrault; Laure Bihannic; Stephanie Puget; Xiao-Nan Li; James M Olson; Giles W Robinson; R Kiplin Guy; Clinton F Stewart; Amar Gajjar; Martine F Roussel Journal: Cancer Cell Date: 2014-03-27 Impact factor: 31.743
Authors: Conrad R Cruz; Ulrike Gerdemann; Ann M Leen; Jessica A Shafer; Stephanie Ku; Benjamin Tzou; Terzah M Horton; Andrea Sheehan; Amanda Copeland; Anas Younes; Cliona M Rooney; Helen E Heslop; Catherine M Bollard Journal: Clin Cancer Res Date: 2011-09-09 Impact factor: 12.531
Authors: Sathivel Chinnathambi; Susan Wiechert; Ann Tomanek-Chalkley; Michael C Winter; Jackie R Bickenbach Journal: J Dermatol Date: 2012-04-09 Impact factor: 4.005
Authors: Chana L Glasser; Alice Lee; Don Eslin; Lianna Marks; Shakeel Modak; Julia L Glade Bender Journal: J Pediatr Hematol Oncol Date: 2017-10 Impact factor: 1.289
Authors: Floor A M Duijkers; Renee X de Menezes; Inès J Goossens-Beumer; Dominique J P M Stumpel; Pieter Admiraal; Rob Pieters; Jules P P Meijerink; Max M van Noesel Journal: Cell Oncol (Dordr) Date: 2013-07-18 Impact factor: 6.730